Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07946393

Preoperative CA 19-9 and the Pattern and Timing of Recurrence After Pancreatoduodenectomy (Whipple Operation) for Pancreatic Cancer

Sponsor: Minia University

View on ClinicalTrials.gov

Summary

Surgery to remove the head of the pancreas (pancreatoduodenectomy, also called the Whipple operation), usually followed by chemotherapy, is the only treatment that offers long-term survival for cancer in the head of the pancreas (pancreatic ductal adenocarcinoma). Even so, the cancer comes back (recurs) in most patients. Where it comes back first (around the operation site, in the liver, in the lining of the abdomen, in the lungs or elsewhere) and how soon it comes back both affect survival, the choice of further treatment and how patients should be followed up. CA 19-9 is a blood test measured routinely before this operation. A high level is known to be linked with shorter survival, but whether it also predicts where and when the cancer will recur is uncertain and, to the investigator's knowledge, has not been studied in patients treated in Egypt. Jaundice, which is common in these patients, can raise CA 19-9 falsely, so this study uses only CA 19-9 values measured when the blood bilirubin level was close to normal (2 mg/dL or less). This is a retrospective study of existing medical records. It includes adults who had a Whipple operation for this cancer at the Hepatopancreatobiliary and Surgical Oncology Unit, Liver and GIT Hospital, Minia University, Egypt, between January 2017 and December 2024, with follow-up information from Minia Oncology Centre. No patient will receive any test or treatment for the study, and no care will be changed. Patients will be compared according to their preoperative CA 19-9 level (37 U/mL or less versus more than 37 U/mL). The two main questions are whether the preoperative CA 19-9 level is linked to (1) the site of the first recurrence and (2) the time from surgery to recurrence. A recurrence will count only when confirmed by scans or biopsy, never by a rising CA 19-9 alone, and it will be classified by independent doctors who do not know the patients' CA 19-9 results. Other questions include recurrence within 6 and 12 months of surgery, survival, and whether CA 19-9 adds useful information to the routine findings available before surgery. The investigator expects that patients with a high CA 19-9 will more often recur first in the liver or the lining of the abdomen and will recur sooner, whereas patients with a normal level will recur later and more often only near the operation site. The findings may help tailor follow-up after surgery, identify patients who might benefit from chemotherapy before surgery, and identify patients whose cancer is likely to come back only at the operation site, who might be considered for further local treatment.

Official title: Correlation of Preoperative Serum CA 19-9 With the Pattern and Timing of Recurrence After Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Retrospective Cohort Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

180

Start Date

2026-12-01

Completion Date

2027-04-30

Last Updated

2026-11-18

Healthy Volunteers

No

Interventions

PROCEDURE

Pancreatoduodenectomy

Curative-intent pancreatoduodenectomy (classical Whipple or pylorus-preserving; open or minimally invasive) with standard ISGPS lymphadenectomy, with mesopancreatic excision, an artery-first approach and venous resection where indicated, performed as routine care at the Liver and GIT Hospital, Minia University, between 1 January 2017 and 31 December 2024. Specimens were reported synoptically against the AJCC eighth edition dataset, applying the 1 mm margin rule. The operation is not assigned, scheduled or modified by the study; operative and pathology data are extracted retrospectively from existing records.

DIAGNOSTIC_TEST

Index preoperative serum CA 19-9

Exposure of interest. Serum CA 19-9 measured during routine preoperative care by electrochemiluminescence immunoassay and retrieved from laboratory records; no sample is taken for the study. Index value: the last CA 19-9 within 30 days before operation with a contemporaneous total bilirubin ≤2 mg/dL (≤34 µmol/L) drawn within 72 hours of the CA 19-9 sample; after preoperative biliary drainage, the post-drainage value meeting this criterion (pre-drainage values are recorded but never used). Where several values qualify, the one closest to surgery is used. Analysed as binary (\>37 vs ≤37 U/mL; primary contrast), ordinal (\<2, 2-37, \>37-200, \>200 U/mL) and continuous (log2\[CA 19-9 + 1\]) variables.

Locations (2)

Minia university oncology hospital

Minya, Minya Governorate, Egypt

Liver and GIT Hospital, Faculty of Medicine, Minia University

Minya, Minya Governorate, Egypt